20191209 PR Investors Meeting agenda 2020
Category: dates
Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
https://www.transgene.fr/wp-content/uploads/posters/Poster-actox2019.pdf Clémentine Spring-Giusti et al. American College of Toxicology – 40th Annual Meeting Download the poster here Poster Presentation
Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
20191114 Résultats T3-2019 EN
Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download the poster here Poster Presentation
Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Transgene SITC 2019 Poster Jean-Baptiste Marchand et al. SITC 2019 Download the poster here Poster Presentation
Transgene Will Participate in the Jefferies 2019 London Healthcare Conference
20191022 – Transgene PR Jefferies EN
Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
20190930 PR TG4001 ESMO EN
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation
Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
20190918-Transgene-H1-2019-RESULTS-EN
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
20190916 PR ANSM TG4050 EN